Message from the Director

Diabetes and obesity have reached epidemic proportions in the US and around the world. Founded in 2008, the Mount Sinai Diabetes Obesity Metabolism Institute (DOMI), the research counterpart to Mount Sinai’s nationally ranked Division of Diabetes Endocrinology and Bone Disease, was created in response to the rise of obesity, diabetes, and metabolic syndrome. It endeavors at the forefront of research to cure these disorders by developing better therapeutic and prevention strategies through basic and clinical research. DOMI is a world leader in diabetes and obesity research, with broad focuses on many sub-disciplines within this space, ranging from very basic science through translational research, to community-based education and prevention programs. 

Areas of notable strength within the DOMI include:

  • NIH, ADA and JDRF support for diabetes and obesity research of ~$12M in 2021, with strong support extending to 2026 among 18 Principal Investigators.
  • Excellent US News and World Reports Rankings of Diabetes Programs: #7 in 201 9 and #11 in 2020 among 120 Divisions and 6000 hospitals in the US.
  • Renewal of the joint Albert Einstein College of Medicine and Mount Sinai Diabetes Research Center, the “Einstein-Sinai DRC”, a NIDDK P-30 grant through 2025. This is one of the 16 DRCs in the US.
  • Nationally recognized research programs in human beta cell regeneration for Type 1 diabetes (T1D) and Type 2 diabetes (T2D); medicinal chemistry and drug discovery; human and rodent adipocyte biology; brain control of appetite, metabolism and energy expenditure; clinical trials and use of the artificial pancreas; the autoimmunity of Type 1 diabetes; polycystic ovarian disease; clinical trials in obesity; bariatric surgery.
  • Strong interactions with the outstanding Adult Division of Endocrinology, Diabetes and Bone Disease and the Division of Pediatric Endocrinology.
  • A Diabetes and Obesity Metabolism Clinical Research Center at Mount Sinai Morningside (formerly St. Luke’s Hospital) fully equipped for clamp, body composition and whole body energy expenditure and balance studies clinical trials.
  • World class genomics, bioinformatics and biomedical computing employed in whole exome, whole genome, GWAS, gene expression, single cell studies, CyTOF, population, structural biology, drug discovery, of T2D, obesity, polycystic ovarian disease, human insulinoma and other disorders of metabolism as well as a large, electronic medical record-linked personalized medicine program.
  • High quality research publications in the NEJM, Science, Science Translational Medicine, Science Reports, Cell, Cell Metabolism, Nature, Nature Medicine, Nature Communications, Nature Metabolism, JCI, PNAS, and others.
  • The largest diabetes care network in New York City, and the third largest health care system in the US.
  • New York City’s largest Artificial Pancreas clinical program.
  • Excellence in vascular and renal complications of diabetes.
  • Community outreach and education programs for prevention and management of diabetes.
  • Discovery of the world’s first potent and reproducible human beta cell regenerative classes of drugs.
  • Outstanding, state-of-the-art research facilities for high-throughput drug screens, monoclonal antibody generation, high-content imaging, human and rodent bioinformatics and genomics, facilities for complete state-of-the-art rodent metabolic phenotyping, flow cytometry and cell sorting, in vivo animal and human imaging, microsurgery cores, advanced microscopy of all types, and real-time, electronic medical record-based bi-directional personalized medicine.
  • Strong, collaborative and complimentary relationships with the Diabetes Centers at Columbia University College of Physicians and Surgeons, Albert Einstein College of Medicine, NYU and New York Hospital/Weill College of Medicine.

Andrew Stewart, MD
Director, Diabetes, Obesity and Metabolism Institute
Irene and Dr. Arthur Fishberg Professor of Medicine